Slightly off-topic, but would the AVR animal study have been designed in a way so as to satisfy FDA equivalent in EU, S/E Asia etc or is it a FDA or bust type of report?
Im sure the FDA requirements would be up there with regards to stringency and results would be valid for most endpoints, but i know with other Bio-techs i'm in, sometimes different regulators seek slightly different end points to measure a products effectiveness.
Cheers
Ann: Key Animal Study for EFS Submission Completed, page-26
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$11.90 |
Change
-0.250(2.06%) |
Mkt cap ! $256.8M | |||
| Open | High | Low | Value | Volume |
| $12.15 | $12.15 | $11.90 | $18.71K | 1.572K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 59 | $11.90 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $12.10 | 661 | 2 |
View Market Depth
| Last trade - 10.40am 07/10/2024 (20 minute delay) ? |
| AVR (ASX) Chart |